Lastly, we analyzed melanoma samples taken from patients prior to BRAF inhibitor therapy (N=9), during early treatment with vemurafenib (N=2, 960 mg twice daily) or dabrafenib (N=7, a total daily dose of ≥200 mg daily), and, at the point of clinical progression while still on the BRAF inhibitor (N=5). Here, BRAF is linked to melanoma.